What SkyePharma does

Skyepharma Production S.A.S. is a privately held French Contract Development and Manufacturing Organization (CDMO) specializing in complex oral solid dosage forms — tablets, capsules, granules, pellets, and stick-packs. Headquartered in Saint-Quentin-Fallavier (Auvergne-Rhône-Alpes), the company operates from a single integrated cGMP-certified site with multi-regulatory approvals (FDA, ANSM, ANVISA, BPF) that enable supply into more than 160 countries. It employs 217 people, roughly a quarter of whom hold PhDs in chemistry or pharmaceutical sciences. Skyepharma's customer base spans large pharmaceutical companies (Bayer, Teva, Dr. Reddy's, Chiesi, Azurity, Therabel, Advanz), specialty pharma (Bioprojet, Pharmadev), and biotechs (MaaT Pharma, Biophytis, Calliditas), addressing formulation challenges including poor bioavailability, controlled/targeted release, multi-API combinations, HPAPI containment, and small-volume orphan drug production.

The company's competitive differentiation rests on three proprietary patented drug-delivery platforms: Geomatrix® (multi-layer controlled-release tablets, present in 8 commercial products across 80+ countries), Geoclock® (tab-in-tab technology enabling time-programmed release independent of food or pH), and Soctec® (gastro-retentive capsules designed to remain in the stomach for over 9 hours). It also operates four forward-looking R&D programs — GeoBiologicS (oral biologics delivery with University of Bordeaux), NanoMicS/NanoFact (nanoparticle formulations, University of Lyon), GeoColon (colon targeting, University of Lille), and MucoTabS (mucoadhesive platforms, University of Lyon) — plus specialized contained production zones for OEB 4/5 highly potent molecules (450 m², opened November 2024), non-sexual hormones (~1,000 m²), and microbiome therapies (Skyehub-Bioproduction, 1,600+ m², co-developed with MaaT Pharma).

Skyepharma generates revenue across five streams: (1) galenic formulation development services from preclinical through Phase III using Quality by Design methodology; (2) cGMP manufacturing of clinical and commercial oral solid doses; (3) primary and secondary packaging including serialization for multi-market compliance; (4) Skyehub-Bioproduction modular GMP infrastructure offered to biotech clients; and (5) licensing royalties from Geomatrix® and Geoclock®. Pricing is project-based and not publicly disclosed. The go-to-market is direct B2B enterprise sales, with prospecting, RFP management, and commercial negotiation handled by an in-house business development team targeting EU and US markets, supported by participation in industry events such as CDMO Live, CPHI, BayOconnect, and the Orphan Drug Congress.

Name

SkyePharma

Legal name

Skyepharma Production S.A.S.

Website

https://skyepharma.fr

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Skyepharma is a French CDMO specializing in complex oral solid dosage forms (tablets, capsules, pellets) for pharmaceutical and biotech clients, leveraging proprietary controlled-release platforms (Geomatrix®, Geoclock®, Soctec®) and specialized HPAPI, hormone, and bioproduction facilities certified by FDA, ANSM, and ANVISA.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Packaging and Labeling Services (561910)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical CDMO services
• Oral solid dosage manufacturing
• Controlled-release drug delivery
• Pharmaceutical formulation development
• CGMP contract manufacturing

Headquarters

HQ city

Saint-quentin-fallavier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Development Services: Galenic formulation development from early-stage through clinical phase I-III, including analytical development and Quality by Design methodology. Services span from proof of concept to regulatory dossier.
2. cGMP Manufacturing: Manufacturing of oral solid dosage forms including tablets (standard, multi-layer, coated), capsules, granules, and pellets. Covers clinical batches through commercial-scale industrial production, with flexible lot sizes.
3. Pharmaceutical Packaging: Primary and secondary packaging including bottles, blisters, stick-packs, with serialization and aggregation for international regulatory compliance (Europe, USA, Russia, Saudi Arabia).
4. Skyehub-Bioproduction: Dedicated GMP facilities and scientific/quality/production teams offered on a modular basis to biotech companies for clinical (phase 2-3) through industrialization. Includes building access, equipment installation, and turnkey manufacturing solutions.
5. Licensing of Proprietary Technologies: Access to proprietary technologies Geomatrix® and Geoclock® through licensing arrangements for pharmaceutical partners developing controlled-release products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SkyePharma is a French pharmaceutical CDMO that develops, manufactures, and packages complex oral solid dosage forms (tablets, capsules, granules, pellets, stick-packs) for pharmaceutical and biotech clients. Its core offering is built around proprietary controlled-release technology platforms (Geomatrix®, Geoclock®, Soctec®) and includes galenic formulation development, cGMP manufacturing, packaging with serialization, project management, and modular bioproduction services (Skyehub-Bioproduction).

Product overview

SkyePharma is a French Contract Development and Manufacturing Organization (CDMO) specializing in complex solid oral dosage forms, offering an integrated service portfolio from early-stage development through industrial manufacturing and packaging. The core offering centers on proprietary controlled-release technology platforms including Geomatrix® (multi-layer tablets), Geoclock® (programmed-release tab-in-tab technology), and Soctec® (gastro-retentive capsules). SkyePharma provides end-to-end CDMO services including galenic formulation development, pharmaceutical manufacturing of tablets/capsules/granules/stick-packs, packaging with serialization, and regulatory support. The company also operates specialized facilities for highly potent compounds (OEB 4/5), non-sexual hormones, and biopharmaceuticals through its Skyehub-Bioproduction platform. Additional innovation programs include GeoBiologicS (oral biologics delivery), NanoMicS/NanoFact (nanoparticle formulations), GeoColon (colon targeting), and MucoTabS (mucoadhesive platforms).

Differentiator

Problem solved

Functional benefit

Brands

• Skyehub-Bioproduction: A turnkey infrastructure solution offering dedicated GMP-certified facilities, quality systems, industrial support, and a qualified production team for biotech companies, from clinical phases through industrialization.

Products and services

• Geomatrix® Multi-Layer Tablet Technology
• Geoclock® Tab-in-Tab Programmed-Release Technology
• Skyehub-Bioproduction Modular Bioproduction Service
• Galenic Formulation Development Services
• cGMP Pharmaceutical Manufacturing Service
• Pharmaceutical Packaging Service
• Pharmaceutical Project Management Service
• HPAPI Manufacturing (OEB 4/5) Service
• Non-Sexual Hormones Manufacturing Service
• Multi-API Combination Formulation Service

Quantifiable outcome

• Geomatrix® technology used in 8 marketed products distributed in over 80 countries
• +4 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• MaaT PharmacoreStrategic or Co-development Partner · 1 February 2022In February 2022, Skyepharma and MaaT Pharma established a partnership to create the first Skyehub building, a dedicated cGMP (BPF) manufacturing facility for microbiome ecosystem therapies in France. The facility spans over 1,600 m² and represents a unique co-development arrangement where Skyepharma provides turnkey GMP infrastructure, production teams, quality systems, and industrial resources while MaaT Pharma gains exclusive manufacturing capacity for its microbiome therapy products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hovione: Portugal-based CDMO with proprietary particle engineering and controlled-release capabilities; comparable emphasis on complex formulation challenges and pharmaceutical innovation partnerships.
• Fareva: French-headquartered CDMO with broad dosage-form coverage including oral solids; comparable French-based contract manufacturing services to large pharma customers across Europe.
• Catalent: Global CDMO with deep specialty in oral solid dose forms and proprietary softgel/controlled-release technologies; directly comparable service portfolio and customer base to SkyePharma, but at vastly larger scale.
• Adare Pharma Solutions: US-headquartered specialty CDMO built around proprietary oral drug delivery platforms (multiparticulate, taste masking, controlled release); the most direct comparable in terms of differentiated technology + CDMO service integration.
• Recipharm: Swedish-origin CDMO with strong oral solids and inhalation capabilities; comparable European footprint, B2B pharma customer base, and contract development + commercial manufacturing model.
• Delpharm: French CDMO with multiple European sites producing solid, sterile, and liquid dosage forms; geographically proximate peer serving the same French and European pharma customer base.
• Aenova: European-headquartered CDMO specializing in solid oral dosage forms (tablets, capsules, softgels) with multiple EU sites; closely comparable business model, customer base, and proprietary formulation focus.

Emerging players

• Pillar5 Pharma: Canadian specialty CDMO focused on oral solid dose manufacturing including highly potent compounds; emerging peer with niche HPAPI/oral solids capability analogous to SkyePharma's HPAPI zone offering.

Broad incumbents

• Lonza: Global CDMO leader with extensive oral solids, biologics, and cell/gene therapy capabilities; competes with SkyePharma for complex formulation projects but at much greater scale and broader modality coverage.
• Eurofins CDMO: Pharmaceutical CDMO services arm of Eurofins Scientific offering development, manufacturing, and analytical services; broader portfolio but overlaps on formulation development and clinical/commercial supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCSj2WQGvNTrJr6vBqGo_rhA
• LinkedInlinkedin.com/company/skyepharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SkyePharma